IASO Bio and Innovent jointly announce the NMPA acceptance of the new drug application for equecabtagene autoleucel for the treatment of relapsed and/or refractory multiple myeloma

IASO Biotherapeutics

2 June 2022 - IASO Biotherapeutics and Innovent Biologics today jointly announced that the China NMPA has formally accepted the new drug application for a fully human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma.

Equecabtagene autoleucel is the first CAR-T therapy in China that is self-developed with proprietary whole-process product development and the first BCMA-targeting CAR T-cell therapy in China with its NDA formally accepted by the NMPA.

Read IASO Biotherapeutics press release

Michael Wonder

Posted by:

Michael Wonder